UK-CAB 58: HIV and hormonal therapy
Friday 29 April 2016
Programme
| 09.30-09.45 | Arrival |
| 09.45-10.00 | Welcome and introductions, UK-CAB updates |
| 10.00-10.45 | HIV and menopause – Shema Tariq |
| 10.45-11.15 | Community engagement on BHIVA guidelines – Robert James |
| 11.15-11.30 | BREAK |
| 11.30-12.30 | Personal experience: Trans*woman – Catalina Hermes |
| 12.30-14.00 | LUNCH |
| 14.00-15.30 | Community response to NHS PrEP reconsideration –NATAgeing conference feedback – Damian Kelly |
| 15.30-15.40 | BREAK |
| 15.40-16.15 | Study discussion: Linkage to care following HIV diagnosis – Sarah Croxford, UCL Conferences feedback: BHIVA -Dano Wheals, CROI |
| 16.15-16.45 | Member updates Stigma index – Alastair Hudson, London Combined Audit &Outcomes and Drug & Treatment Sub Group – Virginia Cucchi |
| 16.45 | AOB, meeting close |
Presentations from this meeting
The menopause and women living with HIV
PrEP update from NAT
Ageing with HIV conference feedback
Linkage to care following an HIV diagnosis
Stigma index 2015 survey results
Background reading
Menopause
NHS Choices website about Menopause
Prime Study website – Major study into menopause and HIV at UCL.
HIV and menopause (Shema Tariq)
Trans*people
HIV and Vulnerable Populations: Transgender Medicine (Anita Radix) (PowerPoint from BHIVA Annual Conference 2015)
A Trans Man Discusses PrEP and Condomless Casual Sex
HIV i-Base questions about trans issues inc. drug interactions, and surgery
Financial support
The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.
The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.
Companies that develop and market medicines have a responsibility to actively engage with advocacy organisations. HIV positive people and their advocates should also be able to ask manufacturers directly about the safety and efficacy of their products. We should be involved in their proposals for future research.
For a list of companies that support the UK-CAB please see the “about us” page.